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An alternative to oral NSAIDs 
for acute musculoskeletal 
injuries
A topical NSAID can relieve acute musculoskeletal pain, 
with little risk of side eff ects.
PRACTICE CHANGER
For patients with acute musculoskeletal inju-
ries, topical NSAIDs are an eff ective alterna-
tive for pain relief.1 
STRENGTH OF RECOMMENDATION
A: Based on a meta-analysis of 47 high-
quality randomized clinical trials. 
Massey T, Derry S, Moore RA, et al. Topical NSAIDs for acute pain in 
adults. Cochrane Database Syst Rev. 2010;(6):CD007402.
ILLUSTRATIVE CASE
A 47-year-old man limps into your offi ce com-
plaining of ankle pain. The patient is well 
known to you and has a long history of dys-
pepsia, which is aggravated when he takes 
any oral nonsteroidal anti-infl ammatory drug 
(NSAID). He injured his ankle while playing 
basketball. You diagnose acute ankle sprain. 
Would a topical NSAID be a safe option for 
pain relief for this patient?
Patients with tendon and ligament injuries often see their family physi-cian for care. Rest, ice, compression, 
elevation (RICE) therapy is fi rst-line treat-
ment for these injuries.2 Oral NSAIDs, such as 
diclofenac, piroxicam, and ibuprofen reduce 
swelling and lead to a more rapid return to 
activity than RICE alone in patients with an-
kle sprains,3 and relieve pain associated with 
muscle strains, too. Acetaminophen provides 
comparable pain relief and resumption of 
normal activities.4
Help for those who can’t take oral NSAIDs 
Oral NSAIDs, however, are contraindicated 
for patients with a history of gastrointestinal 
bleeding and must be used cautiously in those 
with chronic kidney disease. Some patients 
can’t tolerate the adverse eff ects, which may 
include stomach upset, vomiting, and abdom-
inal pain. Others may have medication inter-
actions that prohibit use of oral NSAIDs. 
Numerous high-quality, randomized, 
double-blinded placebo-controlled trials of 
topical NSAIDs have been conducted in re-
cent years, involving diclofenac—the only 
topical NSAID available in the United States—
as well as other topical agents on the market 
outside of this country. A recent Cochrane re-
view, detailed below, assessed the effi  cacy of 
topical NSAIDs for patients with acute mus-
culoskeletal injuries.
STUDY SUMMARY
Topical NSAIDs provided signifi cant relief 
Th is meta-analysis of 47 high-quality, 
randomized, double-blinded, placebo-
controlled trials included 3455 patients with 
acute strain, sprain, sport, or overuse in-
juries.1 Four of the 47 trials, with a total of 
746 participants, studied topical diclofenac.
Th ere was signifi cant heterogeneity in 
the studies included in the review, but each 
arm of every trial had at least 10 participants 
>16 years of age with a painful musculo-
skeletal injury sustained within the previous 
48 hours. To be included in the Cochrane 
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meta-analysis, participants had to have used a 
topical NSAID at least once a day for ≥3 days. 
Th e primary outcome measure was a 
reduction in pain ≥50% from baseline. Post-
treatment data were obtained approximately 
7 days after the injury. Of the patients receiv-
ing any topical NSAID, 65% (1181/1822) had 
successful treatment, compared with 43% 
(695/1633) receiving a placebo. Th e number 
needed to treat (NNT) with a topical NSAID 
instead of placebo was 4.5 (95% confi dence 
interval, 3.9-5.3) to reduce pain ≥50%.
For patients using topical diclofenac, 
52% (166/319) had a 50% reduction in pain, 
vs 25% (77/307) using a topical placebo. Th e 
NNT for topical diclofenac was 3.7, about the 
same as for oral NSAIDs.5 
❚ Adverse events were rare in the topical 
NSAID group: 6.3% had a local adverse event 
such as a skin reaction vs 5.9% in the topical 
placebo group. Th ere were no systemic ad-
verse events with topical diclofenac. While all 
topical NSAIDs combined showed a few mi-
nor adverse events compared with placebo, no 
serious systemic events were reported. 
WHAT’S NEW
Topical NSAIDs are a useful alternative
Patients now have another option when 
seeking treatment for acute musculoskeletal 
pain. In addition to those who are unable to 
take oral NSAIDs, some patients may prefer 
a topical preparation because of perceived or 
actual side eff ects and safety profi les.
CAVEATS
Dosing intervals were not established 
Th is meta-analysis included studies that exam-
ined a variety of dosing strategies and condi-
tions, so an optimal dosing interval is not clear. 
However, the studies generally found evidence 
of benefi t regardless of the acute condition and 
the amount and type of topical NSAID used. 
Diclofenac had the best results compared with 
other topical NSAIDs. Benzydamine, which is 
not sold in the United States, was the only topi-
cal NSAID not found to be statistically benefi -
cial compared with placebo, based on 3 studies. 
Topical NSAIDs have a small amount of 
systemic absorption, with blood concentra-
tions about 5% of those from oral NSAIDs. How-
ever, patients with a strict contraindication to 
oral NSAIDs (for example, severe allergy) may 
also have a contraindication to topical NSAIDs. 
Also, all patients should be cautioned to avoid 
oral NSAIDs while using a topical preparation.6
CHALLENGES TO IMPLEMENTATION
Topical NSAIDs are costly 
In the United States, topical diclofenac is 
available only by prescription. Th is may cre-
ate accessibility and cost diff erences between 
oral and topical NSAIDs. Th e average cost of 
a typical 10-day acute injury treatment of an 
adult with oral ibuprofen would be about $3 
for plain tablets ($10 for extended release and 
enteric coated), vs about $65 for diclofenac gel, 
$113 for a diclofenac patch, and $66 for a di-
clofenac topical solution (www.drugstore.
com, accessed December 2, 2010).
Physician inertia may also interfere with 
implementation. Physicians may not add a 
new medication to current prescribing op-
tions, although there appear to be no medical 
barriers to topical NSAIDs. Th is meta-analysis 
shows that topical NSAIDs are safe and eff ec-
tive for pain relief from acute injuries.           JFP
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